In: 新闻报道

Jonathan Santomauro对公司和社区的奉献精神受到认可,入选《费城商业期刊》的活力进取新星名单并获得表彰。

美国宾州,霍舍姆—2018年4月17日 全球临床和辅助供应链领导者Ancillare, LP,唯一一家专门为大中型制药、生物技术和医疗器械公司以及外包研发和医疗研究机构提供端到端临床和辅助供应链管理服务的组织,很高兴地宣布其总裁兼联合创始人Jonathan Santomauro被《费城商业期刊》评为“2018年40岁以下40大杰出人物”之一。

“40岁以下40大杰出人物”表彰的是费城地区当前及未来的优秀领导者,认可他们的专业卓越,杰出成就和对社区的贡献。Santomauro从400多个提名者中脱颖而出。

Santomauro在确定对临床和辅助供应链行业的单一焦点方面发挥了重要作用,并且最特别的是,他被视作Ancillare 一站式运营(A-TKO™)端到端解决方案背后的驱动主力,这已经彻底改变了行业对临床供应链的处理方式。通过这种和其他商业模式,Ancillare将继续保持在全球临床供应链行业的最前沿,并将继续对临床试验操作,时间线,现场表现和最终患者体验产生直接影响。

Ancillare已从最初的创业组织发展成为一个在全世界各地雇员多达200多人的全球组织。定义并改变了生命科学行业对临床和辅助供应链的感知和管理方式。如今,全球十大顶级制药公司中的八家,全球五大顶级生物技术公司中的三家以及顶尖的两大临床研究机构,都选择让Ancillare管理自己的I-IV阶段临床试验和辅助供应需求。

“能被评选为《费城商业期刊》“40岁以下40大杰出人物”之一是一种荣誉,”Santomauro说: “我很幸运能够为全球各地患者的临床试验操作和创新疗法的发展带去直接影响。”

Santomauro活跃于当地商业社区,他是YPO(前青年主席组织)费城分会的成员,还是康奈尔大学的创业咨询委员会的长期成员,并在那里获得了工商管理硕士学位和文学学士学位。

Santomauro将于5月10日星期四在费城SugarHouse赌场举行的颁奖典礼上领奖。

关于Ancillare, LP

Ancillare是唯一一家专注于全球临床和辅助供应链的组织。Ancillare通过定制的端到端Ancillare供应计划,为全球临床试验的赞助商助力,使新疗法的开发人员能够使用简化的流程,广泛的全球购买力,庞大的仓库网络和经过验证的临床,采购,运营,物流和监管专家团队,优化其临床研究供应链 。Ancillare的一站式运营(A-TKO™)模式通过降低临床试验的总体成本和周期时间,并大大提高价值链各个层面的运营效率,可同时应对临床和辅助供应链的复杂性和全球化。

Ancillare已在100多个国家的80000个临床站点支持了1500多项临床试验,其中包括美国,英国和新加坡的主供应站,以及阿根廷,澳大利亚,巴西,加拿大,智利,中国,哥伦比亚,印度,以色列,日本,韩国,墨西哥,巴拿马,秘鲁,菲律宾,俄罗斯,南非,台湾和乌克兰的战略供应站。要了解更多信息,请访问Ancillare.com

 

Approaching Brexit deadline, new licensure will enable continuous global clinical trial operations for sponsors and CROs

HORSHAM, PA. — January 31, 2018. Global Clinical and Ancillary Supply Chain leader Ancillare, LP, the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations, today announced it has been awarded a Wholesale Distribution Authorization (WDA) for Human use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA).

The award, which comes in response to the United Kingdom’s anticipated departure from the E.U.—commonly called “Brexit”—will allow Ancillare to continue to support study sponsors’ European needs, even while Brexit’s impact on pharmaceutical supply chains remains unclear. The licensure is a critical victory for the dozens of study sponsors, CROs and MROs for whom the U.K. market is a vital link in complex, global clinical trial portfolios and supply chains.

“I think [the license is] a testament to the integrity and dedication of our global team,” said Joanne Santomauro, CEO, Ancillare. “No matter how rapidly or exponentially things have changed on the global stage, we’ll always be ready to respond in service to our sponsors.”

Ancillare received the license following an intensive evaluation, auditing and inspections process. Among the qualifying criteria for the license was that Ancillare was in full compliance with the 2012 Human Medicines Regulations, and with the requirements of Good Distribution Practice (GDP). Ancillare’s WDA will enable ongoing wholesaling and distribution activities—including procurement, holding, supply and export—from its European regional office and master depot in Milton Keynes.

“I’m proud that Ancillare has emerged even better equipped to meet the clinical and ancillary supply chain needs of study sponsors,” Santomauro added.

In response to its confirmed regulatory compliance status, as well as ongoing Brexit requirements, Ancillare anticipates adding staff at its United Kingdom office, in order to drive global expansion efforts throughout Europe, the Middle East, Africa and Asia-Pacific. Ancillare expects to announce the staff changes later in Q1 2018.

 

About Ancillare, LP

Ancillare is the only organization of its kind with an exclusive focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s Turn-Key Operations (A-TKO™) model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improving operational efficiency across all levels of the value chain.

Ancillare has supported more than 1,500 clinical trials across 80,000 clinical sites over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine. To learn more, visit ancillare.com.

HORSHAM, PA. — Global Clinical and Ancillary Supply Chain leader Ancillare, LP—the only organization exclusively serving the end-to-end clinical and ancillary supply chain management needs of large- and middle-market pharmaceutical, biotechnology, and medical device companies, as well as contract and medical research organizations—today announced that David J. DelCollo, Esq., its primary in-house counsel, has been awarded both “Top 100 Lawyer” and “Top 40 Under 40” recognitions.

The recognitions come on the heels of DelCollo’s first year as Ancillare’s general counsel. Prior to joining Ancillare, he served as Senior Counsel for Bioclinica, where he worked to develop and protect the company’s intellectual property and licensing rights. DelCollo brought more than a decade of legal experience in practice areas such as corporate, contract and healthcare law to Ancillare—knowledge which he made quick use of, according to Ancillare leadership.

“David has made tremendous contributions this year and I think these awards are apropos,” said Joanne Santomauro, CEO at Ancillare. “He’s a skilled attorney. Not only as he helped [Ancillare] define our legal policies, he’s put us on a path to a more secure future.”

Prior to his success in corporate law, DelCollo represented the Commonwealth in the courtroom. As an Assistant District Attorney in the Greater Philadelphia Area, he personally prosecuted over 1,000 cases, winning favorable verdicts and outcomes 97% of the time.

DelCollo holds a J.D. from Widener University School of Law, where he was a member of the Trial Advocacy team.

The recognition of “Top 100 Lawyer” was awarded by executive profile publication International Top 100 Magazine. DelCollo’s “Top 40 Under 40” spotlight will be featured a forthcoming 2018 edition of the same magazine.

About Ancillare, LP

Ancillare is the only organization of its kind with a singular focus on the global clinical and ancillary supply chain. Ancillare arms sponsors of global clinical trials with a customized, end-to-end Ancillare Supply Plan, enabling developers of new therapies to optimize their clinical study supply chains using streamlined processes, extensive global buying power, a vast depot network and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s A-TKO™ model embraces the complexities and globalization of the clinical and ancillary supply chain by reducing both the overall cost and cycle time of clinical trials, and greatly improves operational efficiency across all levels of the value chain.

Ancillare has experience in working over 100 countries with master depots in United States, United Kingdom, and Singapore, and strategic depots in Argentina, Australia, Brazil, Canada, Chile, China, Colombia, India, Israel, Japan, Korea, Mexico, Panama, Peru, Philippines, Russia, South Africa, Taiwan, and Ukraine.